Officer and Director Files Intent to Sell $3.84M in Stock, Following $6.13M in Recent Sales
APGE has more than doubled off its 52-week low of $26.2 on light trading volume (0.1× avg).
Summary
An Officer and Director at Apogee Therapeutics has filed to sell $3.84 million in company stock, adding to $6.13 million in sales over the last three months, totaling nearly $10 million in insider dispositions.
Key Events · Ownership and Investor Activity · APGE
-
Officer/Director Files Intent to Sell
Michael Henderson, an Officer and Director, filed a Form 144 to sell 60,000 shares of common stock, valued at approximately $3.84 million.
-
Follows Significant Recent Sales
This proposed sale comes after Henderson sold 80,000 shares for gross proceeds of $6.13 million in the past three months.
-
Total Insider Disposition Nears $10 Million
The combined value of proposed and recent sales by this insider totals approximately $9.97 million.
-
Sales Under 10b5-1 Plan
The sales are being conducted under a Rule 10b5-1 trading plan adopted on August 13, 2025.
Analysis · APGE · Life Sciences
Michael Henderson, an Officer and Director at Apogee Therapeutics, Inc., has filed a Form 144 indicating his intent to sell 60,000 shares of common stock, valued at approximately $3.84 million. This proposed sale follows previous sales by Henderson totaling $6.13 million over the past three months, bringing his total recent and intended sales to nearly $10 million. While the sales are under a pre-planned 10b5-1 program, the cumulative value represents a significant reduction in a key insider's holdings, which could be interpreted negatively by investors.
At the time of this filing, APGE was trading at $62.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $26.20 to $84.56. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.